[Hepatotoxic effects of 2-methyl-2-(p-(1,2,3,4-tetrahydro-1-naphthyl)-phenoxy)propionic acid (Ciba 13,437-Su)].
D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000627:therapeutic use / Q000633:toxicity; D001219:Aspartate Aminotransferases / Q000097:blood; D001706:Biopsy; D056486:Chemical and Drug Induced Liver Injury; D005234:Fatty Liver / Q000139:chemically induced; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects; D008134:Long-Term Care; D008875:Middle Aged; D009281:Naphthalenes / Q000009:adverse effects* / Q000627:therapeutic use / Q000633:toxicity; D010636:Phenols / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity; D011422:Propionates / Q000009:adverse effects* / Q000627:therapeutic use / Q000633:toxicity; D014280:Triglycerides / Q000097:blood
D000924:Anticholesteremic Agents; D008055:Lipids; D009281:Naphthalenes; D010636:Phenols; D011422:Propionates; D014280:Triglycerides; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase
Zur Frage hepatotoxischer Nebenwirkungen von 2-Methyl 2-(p(1,2,3,4-tetrahydro-1-naphthyl)-phenoxy)-propionsäure (Ciba 13,437-Su.